^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
11P - Novel HDAC6 inhibitors show anti-lymphoma activity alone and in combination with venetoclax and copanlisib
Published date:
03/03/2022
Excerpt:
The three most active HDAC6i (SW-117, SW-101, WT-36-87), plus SW-113 that showed negligible activity as a single agent, were tested in combination with the PI3Kα/δ inhibitor copanlisib and the BCL2 inhibitor venetoclax, in DOHH2 and SU-DHL-4. All four HDAC6i showed enhanced anti-proliferative activity in at least one of the combinations tested. SW-117 and SW-101 showed similar benefit when combined with either copanlisib or venetoclax.
